Immuno-Oncology | Specialty

Dr. Ferris on CheckMate-141 Trial in Head and Neck Cancer

April 20th 2016

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the CheckMate-141 trial, which found that treatment with single-agent nivolumab (Opdivo) reduced the risk of death by 30% and doubled 1-year overall survival (OS) rates compared investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN).

Dr. Khleif on Next Steps to Take With Immunotherapy

April 19th 2016

Samir N. Khleif, MD, director, GRU Cancer Center, discusses next steps researchers and physicians need to take with immunotherapy in the field of oncology.

Nivolumab Doubles 1-Year OS Rates in Head and Neck Cancer

April 19th 2016

Treatment with single-agent nivolumab reduced the risk of death by 30% and double 1-year overall survival rates compared investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma.

PD-L1 Expression Assays Show Similar Performance for NSCLC

April 19th 2016

Three currently available assays for PD-L1 expression exhibited a high degree of correlation in a comparative study involving archived lung cancer tissue.

Pembrolizumab Granted Breakthrough Designation for Hodgkin Lymphoma

April 18th 2016

The FDA has granted a breakthrough therapy designation to pembrolizumab as a treatment for patients with relapsed or refractory classical Hodgkin lymphoma.

Yong-Chen William Lu on Adoptive T-Cell Therapy in Solid Tumors

April 18th 2016

Yong-Chen William Lu, PhD, a fellow in the Surgery Branch of the National Cancer Institute, discusses a CD4 T-cell immunotherapy targeting MAGE-A3 that is showing early clinical responses in patients with metastatic cancer.

Dr. Hodi on Long-Term Survival Data for Nivolumab in Melanoma

April 17th 2016

F. Stephen Hodi, MD, director of the Melanoma Center at Dana-Farber Cancer Institute, discusses the results of the longest follow-up survival study of patients with advanced melanoma who were treated with single-agent nivolumab (Opdivo).

Nivolumab Shows Impressive Long-Term OS in Melanoma

April 17th 2016

Single-agent nivolumab demonstrated a robust 5-year overall survival rate of 34% for heavily pretreated patients with metastatic melanoma who had not received prior ipilimumab.

Dr. Raffaele Califano on Immunotherapy in Small-Cell Lung Cancer

April 16th 2016

Raffaele Califano, MD, consultant in medical oncology at the Christie NHS Foundation Trust and University Hospital of South Manchester, discuses the potential for immunotherapy in small-cell lung cancer (SCLC).

Higher Cytokine Levels Improve Nivolumab Efficacy in Squamous NSCLC

April 16th 2016

Efficacy and safety remained strong 2 years following treatment with nivolumab for patients with advanced, refractory, squamous non-small–cell lung cancer, with an indication that cytokine levels could predict long-term outcomes.

Dr. John Haanen on the Role of PD-L1 in Lung Cancer

April 14th 2016

John Haanen, MD PhD, epartment of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, discussed the role of PD-L1 as a biomarker in lung cancer.

FDA Grants Nivolumab Priority Review in Hodgkin Lymphoma

April 14th 2016

The FDA has granted nivolumab (Opdivo) a priority review for use in previously treated patients with classical Hodgkin lymphoma.

FDA Grants Priority Review to Pembrolizumab for Head and Neck Cancer

April 13th 2016

The FDA has granted a priority review designation to pembrolizumab (Keytruda) as a treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma.

Dr. Levy on Impact of Nivolumab, Pembrolizumab Approvals in NSCLC

April 12th 2016

Benjamin P. Levy, MD, assistant professor of Medicine, Hematology, and Medical Oncology at Mount Sinai Hospital, discusses how nivolumab (Opdivo) and pembrolizumab (Keytruda) have impacted the treatment landscape of non–small cell lung cancer.

Dr. Choueiri on Using Immunotherapy to Treat RCC

April 11th 2016

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses why community oncologists should utilize immunotherapy agents to treat patients with renal cell carcinoma.

FDA Grants Atezolizumab Priority Review in Lung Cancer

April 11th 2016

The FDA has granted a priority review to atezolizumab for the treatment of patients with locally advanced or metastatic non–small cell lung cancer who express PD-L1 and have progressed after a platinum-containing regimen.

Study Supports Immunotherapy/Radiation Combo in Head and Neck Cancer

April 8th 2016

Jonathan D. Schoenfeld, MD, discusses potential synergy between radiation therapy, given with or without chemotherapy, and immune checkpoint inhibitors in patients with squamous cell carcinoma of the head and neck.

Nivolumab Approved in Europe for Renal Cell Carcinoma

April 7th 2016

The European Commission has approved nivolumab (Opdivo) for use in previously treated patients with advanced renal cell carcinoma.

Europe Expands Nivolumab Lung Cancer Approval

April 7th 2016

The European Commission has approved nivolumab (Opdivo) for the treatment of patients with nonsquamous non–small cell lung cancer, regardless of PD-L1 levels.

Dr. Atkins on Adjuvant Ipilimumab in Melanoma

April 7th 2016

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of Oncology and Medicine, Georgetown University School of Medicine, discusses the adjuvant use of ipilimumab (Yervoy) in patients with melanoma.

NEXT PAGE
PREVIOUS PAGE